An estimated 50 million women in Asia are at risk of becoming infected with HIV from their intimate partners. Evidence from many Asian countries indicates that these women are either married or in long-term relationships with men who engage in high-risk sexual behaviours. These findings are published in a new report by UNAIDS, its Cosponsors and civil society partners entitled HIV Transmission in Intimate Partner Relationships in Asia, being released today at the 9th International Congress on AIDS in Asia and the Pacific in Bali.

The HIV epidemics in Asia vary between countries in the region, but are fuelled by unprotected paid sex, the sharing of contaminated injecting equipment by injecting drug users, and unprotected sex among men who have sex with men. Men who buy sex constitute the largest infected population group - and most of them are either married or will get married. This puts a significant number of women, often perceived as ‘low-risk’ because they only have sex with their husbands or long-term partners, at risk of HIV infection.

It is estimated that more than 90% of the 1.7 million women living with HIV in Asia became infected from their husbands or partners while in long-term relationships. By 2008, women constituted 35% of all adult HIV infections in Asia, up from 17% in 1990.

“HIV prevention programmes focused on the female partners of men with high-risk behaviours still have not found a place in national HIV plans and priorities in Asian countries” said Dr Prasada Rao, Director, UNAIDS Regional Support Team Asia and the Pacific, speaking at the launch of the report. “Integration of reproductive health programmes with AIDS programmes and the delivery of joint services to rural and semi-urban women are the key to reducing HIV transmission among intimate partners.”

In Cambodia, India and Thailand, the largest number of new HIV infections occur among married women. In Indonesia, where HIV was initially concentrated among drug users, the virus is now spreading quickly into sex work networks, including long-term partners and sex workers. Research from several Asian countries indicates that between 15% and 65% of women experience physical and/or sexual violence in intimate partner relationships, placing them at increased risk of HIV infection. According to studies in Bangladesh, India and Nepal, women exposed to intimate partner violence from husbands infected with HIV through unprotected sex with multiple partners were seven times more likely to acquire HIV compared to women not exposed to violence and whose husband did not have sex with multiple partners.

The strong patriarchal culture in Asian countries severely limits a woman’s ability to negotiate sex in intimate partner relationships, according to the report. While there is a societal toleration of extramarital sex and multiple partners for men, women are generally expected to refrain sex until marriage and remain monogamous thereafter.

“Discrimination and violence against women and girls, endemic to our social fabric, are both the cause and consequence of AIDS,” said Dr Jean D’Cunha, Regional Director, UNIFEM South Asia. “Striking at the root of gender inequalities and striving to transform male behaviours are key to effectively addressing the pandemic.”

The report also indicates that the female partners of migrant workers have been shown to be at increased risk of HIV infection when the latter return from working in countries with high HIV prevalence. A study in Viet Nam showed that married migrant workers reported having commercial sex partners and low condom use.

To prevent HIV transmission among intimate partner relationships, the report outlines four key recommendations:

1. HIV prevention interventions must be scaled-up for men who have sex with men, injecting drug users, and clients of female sex workers and should emphasize the importance of protecting their regular female partners.
2. Structural interventions should be initiated to address the needs of vulnerable women and their male sexual partners. This includes expanding reproductive health programmes to include services for male sexual health.
3. HIV prevention interventions among mobile populations and migrants must be scaled-up and include components to protect intimate partners.
4. Operational research must be conducted to obtain a better understanding of the dynamics of HIV transmission among intimate partners.

“The work that has been started around prevention of HIV transmission in intimate partner relationships is incredibly important because it means a new way of doing our work,” said Vince Crisostomo, Regional Coordinator, Seven Sisters (Coalition of Asia Pacific Regional Networks on HIV/AIDS). “The ultimate goal is the empowerment of women and it shows that the responsibility is on both sides.”

UNAIDS, its Cosponsors, including UNDP and UNFPA, and partners are organizing a symposium today at the conference to address HIV and intimate partner transmission. The aim is to take stock of evidence showing the increasing vulnerability of women to HIV transmission from their intimate partners and address critical policy and programme challenges.

Source
UNAIDS

A U.S.-backed vaccine experiment in Thailand has for the first time demonstrated a “small but measurable” benefit in preventing HIV infection, the Washington Post reports (Brown, Washington Post, 9/24). Col. Jerome Kim, a physician involved with the trial who is manager of the army’s HIV vaccine program, said that although the reduction in transmission was small, it is statistically significant and means the vaccine was 31.2% effective (McNeil, New York Times, 9/25). According to the Post, the “chief usefulness” of the vaccine is “likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.” The vaccine is not expected to be licensed or produced in large amounts, and it is unlikely that countries would consider it effective enough to be used as a public health measure to reduce the spread of HIV. Nonetheless, the findings are considered a milestone, as they mark the first positive results of an HIV vaccine after two decades of experiments (Washington Post, 9/24).

The vaccine combines Sanofi-Pasteur’s ALVAC canary pox vaccine and AIDSVAX, a failed HIV vaccine made by VaxGen, which is owned by the not-for-profit Global Solutions for Infectious Diseases (Fox, Reuters, 9/24). The six-year study involved 16,000 Thai men and women and was run by the U.S. Army, NIH and Thailand’s Ministry of Public Health. According to the Post, about 40% of the participants were women, and many were employed in shipping and manufacturing enterprises along the Thai coast. A few were injection drug users and men who have sex with men — two groups considered at high risk for HIV transmission. Researchers randomly assigned participants to receive the vaccine or a placebo. Participants were counseled on methods of HIV prevention and advised to use condoms (Washington Post, 9/24).

The participants received six immunizations over six months, two with AIDSVAX and four with ALVAC (Reuters, 9/24). Fifty-one of the 8,197 vaccinated people became infected with HIV in the three years after the shots, compared with 74 of the 8,198 people who received placebos (Washington Post, 9/24). Further details of the study, which cost $105 million, will be presented at a vaccine conference in Paris in October (Marchione, AP/San Francisco Chronicle, 9/24).

Researchers said the vaccine, known as RV 144, “protected too few people to be declared an unqualified success,” and they were also “puzzled” by the trial’s results because the vaccine did not change the amount of HIV in a person’s blood compared with someone who received a placebo, the New York Times reports. A vaccine that offers partial protection typically lowers the viral load. However, this did not occur in the trial, which suggests that the vaccine does not produce neutralizing antibodies — which attack virus cells — like most vaccines, according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which paid for most of the trial. He said the vaccine may produce “binding antibodies,” which attach themselves to and empower effector cells, a type of white blood cell attacking the virus (McNeil, New York Times, 9/25).

Fauci said, “Conceptually, we know a vaccine is possible,” adding, “Whether the vaccine is going to look anything like this one, I don’t know. But at least we know it can be done” (Washington Post, 9/24). Mitchell Warren, executive director of AVAC, the AIDS Vaccine Advocacy Coalition, said that the results of the study are “hugely exciting and, frankly, unexpected,” adding that although RV 144 “is not the vaccine that ends the epidemic,” it is “a fabulous new step that takes us in a new direction” (New York Times, 9/25).

Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women’s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women’s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2009 The Advisory Board Company. All rights reserved.